By Paul Sandle LONDON (Reuters) - Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. Baxalta rebuffed the offer on Tuesday and said in a statement that Shire's unsolicited offer significantly undervalued the company. Shire's all-share offer values each Baxalta share at $45.23, based on Aug. 3 market prices.
By Angeliki Koutantou and Lefteris Karagiannopoulos ATHENS (Reuters) - Both Greece and its lenders said on Tuesday they were optimistic they could broker a deal within days on a multi-billion euro bailout, striking a surprisingly upbeat tone on a process previously fraught with bitterness. A bailout worth up to 86 billion euros ($94.5 billion) must be settled by Aug. 20 -- or a second bridge loan agreed -- if Greece is to pay off debt of 3.5 billion euros to the European Central Bank that matures on that day. Wrapping up a day of talks in Athens, Greek Finance Minister Euclid Tsakalotos said negotiations were going better than expected.
New orders for U.S. factory goods rebounded strongly in June on robust demand for transportation equipment and other goods, a hopeful sign for the struggling manufacturing sector. The Commerce Department said on Tuesday new orders for manufactured goods increased 1.8 percent after declining 1.1 percent in May. "We are moving past the very weak period for the manufacturing sector from early on this year, but that activity has yet to meaningfully increase," said Daniel Silver, an economist at JPMorgan in New York.
U.S. drugmaker Pfizer gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira after pledging to sell some drugs to allay competition concerns. "The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development," the European Commission said. The deal will boost Pfizer's portfolio of generic injectable drugs and copies of biotech medicines.